Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of nerandomilast in systemic sclerosis
NL-OMON61445Phase 3Not yet recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of nerandomilast in systemic sclerosis (SSc), sponsored by Boehringer Ingelheim. Primary endpoint: Time to first occurrence of disease progression or all-cause death. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
nerandomilast
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NL-OMON61445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61445.